First Wave BioPharma's stock price has surged due to the achievement of its enrollment target for the Phase 2 SPAN trial. This milestone indicates progress in the development of their adrulipase treatment for exocrine pancreatic insufficiency in cystic fibrosis patients. The positive news has increased investor confidence, leading to a significant rise in the stock price. The topline results from the study, expected by mid-2023, will be a critical factor in determining the future performance of the stock.